ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO822

Outcomes of Kidney Transplantation in Cystic Fibrosis

Session Information

Category: Transplantation

  • 2002 Transplantation: Clinical


  • Stevanovic, Mirjana, Dartmouth Guarini School of Graduate and Advanced Studies, Hanover, New Hampshire, United States
  • Zimmerman, Asha, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, United States
  • Graber, Martha L., Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, United States

There is a paucity of published data on the outcomes following kidney transplantation in patients with cystic fibrosis (CF).


The USRDS database was used to locate all patients with CF who were diagnosed with ESRD prior to 12/31/2018 undergoing a first kidney transplant. CF patients were compared to non-CF patients undergoing first kidney transplant for the same period. Demographic data was compared using linear and logistic regression. Survival curves for death-censored graft survival and death were compared between groups using cox regression.


A total of 192 patients with CF and 248,820 patients without CF underwent kidney transplantation. Compared to the non-CF population, CF patients were more likely to be female (52.1% vs 40.2%, p < 0.001), have a lower BMI (21.8 vs 27.7, p < 0.001), be white (91.7% vs 67.2%, p < 0.001), have a transplant as first ESRD treatment (22.9% vs 14.1%, p < 0.001), be on dialysis for less time (1.95 yr vs 3.29 yr, p < 0.001), have a living donor transplant (60.4% vs 32.9%, p < 0.001) and less likely to have transplant failure (22.9% vs 30.6%, p = 0.021). Death censored graft survival was no different between the groups (p = 0.28). Five-year death-censored graft survival was 90% vs 85% for patients with CF and non-CF patients, respectively. Patients with CF had worse survival when compared to patients without CF (p < 0.001). Five year and median survival was 92% vs 95% and 17.7 yrs vs 26.8 yrs for CF and non-CF patients, respectively.


There is no difference in death-censored graft survival for patients with CF. Patients with CF have shorter survival after transplantation when compared to a non-CF cohort.


  • Private Foundation Support